In this edition of The Onco’Zine Brief Peter Hofland, Ph.D talks with Tony Polverino, PhD. In September 2918 Polverino joined Zymeworks, a clinical-stage, biopharmaceutical company developing next-generation multifunctional biotherapeutics. He currently serves as the company's Executive Vice Preside
Publish Date: May 25, 2021
There are currently no snippets from Shaping the Possibilities for Patients Everywhere: A Conversation with Zymeworks' Tony Polverino, PhD.
Snippets are an easy way to highlight your favorite soundbite from any piece of
audio and share with friends, or make a trailer for The Onco'Zine Brief
There are currently no playlists containing this audio.
Add this audio track to one of your playlists
In this edition of The Onco’Zine Brief Peter Hofland, Ph.D talks with Tony Polverino, PhD. In September 2918 Polverino joined Zymeworks, a clinical-stage, biopharmaceutical company developing next-generation multifunctional biotherapeutics. He currently serves as the company's Executive Vice President of Early Development and Chief Scientific Officer. Prior to joining Zymeworks, from 2015 until 2018, Polverino was at Kite Pharma, which was acquired by Gilead Sciences in 2017. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody that has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01)[3[ as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas.In our program today Hofland asks Polverino about his work in oncology, his work before joining Zymeworks, and the work he and his co-workers are doing at Zymeworks.About The Onco'Zine BriefThe Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebriefFor more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.comTo sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.Reference A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers - NCT04466891 A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer - NCT04224272 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer - NCT03929666 A Dose-Finding Study of ZW49 in Patients With HER2-Positive Cancers - NCT03821233